Loading
NASDAQHealthcareBiotechnology
Latest quote
$15.95
+$0.32 · +2.05%
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Previous close
$15.95
+$0.32 · +2.05%
Regular session · ET · Market data may be delayed.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Day range
Current $15.95
52-week range
Current $15.95
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
43
Mixed
Risk
68
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Day range
Current $15.95
52-week range
Current $15.95
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$50.00
213.48% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM2.78M0.00%80.51B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI2.69M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 Growth ETFIWO983.83K0.01%14.7B USD0.24%$377.54+0.12%
Vanguard Extended Market ETFVXF975.62K0.00%93.7B USD0.05%$242.66+0.14%
Vanguard U.S. Momentum Factor ETFVFMO804.04K0.04%1.8B USD0.13%$229.8+0.93%
Vanguard Russell 2000 ETFVTWO511.77K0.00%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC368.18K0.02%1.49B USD0.60%$196.25+0.69%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC142.84K0.01%1.09B USD0.20%$90.38+0.33%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard U.S. Momentum Factor ETFVFMOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
